Mabwell Establishes a Licensing and Commercialization Agreement for Denosumab Biosimilars in Malaysian Market
SHANGHAI, April 16, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that it has established a licensing and commercialization agreement with a strategic...
Global First | NMPA Accepts IND Application for Mabwell's Innovative LILRB4/CD3 TCE Bispecific Antibody 6MW5311
SHANGHAI, April 16, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical Products Administration (NMPA) has accepted the Investigational...
Mabwell Announces Acceptance of Supplemental Biologics License Application by NMPA for MAIWEIJIAN (Denosumab)
SHANGHAI, April 16, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with a full industry chain, announced that the National Medical Products Administration (NMPA) has accepted supplemental Biologics License...
SST001, an α-syn PET tracer from Mabwell's incubated company SynuSight Biotech, received NMPA approval to initiate a clinical trial
SHANGHAI, April 15, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that 18F-FD4 (R&D code: SST001), an α-synuclein (α-syn) targeted PET tracer...
Mabwell Announces First-Patient Dosed in Clinical Trial of Novel CDH17-Targeting ADC 7MW4911 in the U.S.
SHANGHAI, Jan. 22, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed in a clinical trial in the U.S. of its independently...
Mabwell Announces First Patient Dosed in Phase II Trial of Anti-IL-11 Antibody for Pathological Scarring
SHANGHAI, Dec. 30, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Phase II clinical trial of its self-developed innovative anti-IL-11 monoclonal...
Mabwell Receives IND Clearance for Novel Anti-ST2 Monoclonal Antibody 9MW1911 to Initiate Phase IIa Study
SHANGHAI, Dec. 24, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that it has received IND clearance from the U.S. Food and Drug Administration (FDA) for its...
Mabwell Announces First-Patient Dosing for Novel CDH17-Targeting ADC 7MW4911
SHANGHAI, Nov. 25, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed in the Phase I/II clinical trial of its independently...
Highlights in Oral Presentation of Mabwell's 9MW2821 at 2025 ASCO
SHANGHAI, June 5, 2025 /PRNewswire/ -- At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, from May 30 to June 3, the results of the Phase Ib/II clinical study of 9MW2821 in combination with Toripalimab for...
Mabwell Receives NMPA Approval for Albipagrastim alfa for Injection (MAILISHENG)
SHANGHAI, May 30, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that Albipagrastim alfa for Injection (trade name: MAILISHENG, R&D code: 8MW0511) developed by its...